BMS-986278 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in ... See More Phase 3 View trial Save trial Hematology Acute Myeloid Leukemia Trial Title Phase BMS-986397 Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Parti ... See Mo...
BMS-986278 is a novel next generation LPA1 antagonist currently in Phase I clinical trials. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and 尾-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human ...
In addition to this Breakthrough Therapy Designation for PPF, the U.S. FDA has also previously granted BMS-986278 fast-track designation and orphan drug designation for the treatment of IPF. Bristol Myers Squibb is continuing the development of BMS-986278 with the globa...
Introduction: BMS-986278, an oral lysophosphatidic acid receptor 1 (LPA) antagonist, has been shown to reduce the rate of decline in percent of predicted FVC (ppFVC) in patients with idiopathic pulmonary fibrosis (IPF) in a phase 2 study (NCT04308681).Aims & Objectives: To assess BMS-...
BMS-986278, a second-generation LPA 1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD. Methods and analysis This phase 2, randomised, double-blind, placebo-controlled, parallel-group, international trial will include adults with IPF or PF-ILD. The trial will...
BMS-986278 is a potent small molecule LPA1 receptor antagonist being investigated for IPF. This study evaluated the safety, tolerability, and PK of oral BMS-986278 in healthy participants (ppts).Methods: IM027-009 is a phase 1, double-blind, placebo (PBO)-controlled, randomized study in ...
Introduction: 18F-BMS-986327 is a PET tracer in development for use in target engagement and dose-receptor occupancy studies of LPA1 antagonists, such as BMS-986278, which is being evaluated in a Phase 2 study in lung fibrosis (NCT04308681). Here, the initial results for a phase 1 study ...